Arrowhead Pharmaceuticals Reports Fiscal 2018 First Quarter Results
Conference Call and Webcast Today at 4:30 p.m. EST
PASADENA, Calif.–(BUSINESS WIRE)–
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial
results for its fiscal 2018 first quarter ended December 31, 2017. The
company is hosting a conference call at 4:30 p.m. EST to discuss results.
Conference Call and Webcast Details
Investors may access a live audio webcast on the Company’s website at http://ir.arrowheadpharma.com/events.cfm.
For analysts that wish to participate in the conference call, please
dial 855-215-6159 or 315-625-6887 and provide Conference ID 4788374.
A replay of the webcast will be available on the company’s website
approximately two hours after the conclusion of the call and will remain
available for 90 days. An audio replay will also be available
approximately two hours after the conclusion of the call and will be
available for 3 days. To access the audio replay, dial 855-859-2056 or
404-537-3406 and provide Conference ID 4788374.
Selected Fiscal 2018 First Quarter and Recent Events
-
Filed a Clinical Trial Application for ARO-AAT, a second generation
subcutaneously administered clinical candidate for the treatment of
alpha-1 antitrypsin deficiency liver disease
-
Filed a Clinical Trial Application for ARO-HBV, a third generation
subcutaneously administered clinical candidate for the treatment of
chronic hepatitis B virus infection
-
Presented new clinical data at HEP DART 2017 demonstrating up to 5.0
log10 reduction in HBV s-antigen and a Sustained Host Response in 50%
of hepatitis B patients following RNAi therapy, ARC-520, in the 2001
open-label extension study
-
Made continued progress on a two-product cardiovascular collaboration
with Amgen, in which one that was previously called ARO-LPA against
the target lipoprotein(a) has been formally nominated as a potential
clinical candidate and which is now referred to as AMG 890 by Amgen
-
Expanded Arrowhead’s cardiometabolic pipeline, which now includes
ARO-APOC3, targeting apolipoprotein C-III, and ARO-ANG3, targeting
angiopoietin-like protein 3 (ANGPTL3); with CTA filings planned around
the end of 2018
-
Achieved continued progress with the Company’s extra-hepatic platform
and pipeline, including:
-
ARO-Lung1, Arrowhead’s first candidate against an undisclosed gene
target in the lung, which achieved nearly 90% target knockdown
following inhaled administration in rodents
-
ARO-HIF2, the Company’s candidate targeting renal cell carcinoma,
which achieved 85% target gene knockdown in a rodent tumor model
-
Selected Fiscal 2018 First Quarter Financial Results
|
|
||||||||
|
ARROWHEAD PHARMACEUTICALS, INC. |
||||||||
|
CONSOLIDATED CONDENSED FINANCIAL INFORMATION (unaudited) |
||||||||
|
|
||||||||
|
|
Three Months Ended |
|||||||
|
December 31, |
||||||||
|
OPERATING SUMMARY |
2017 |
|
2016 |
|||||
|
|
||||||||
|
REVENUE |
$ |
3,509,821 |
$ |
4,365,496 |
||||
|
OPERATING EXPENSES |
||||||||
|
Research and development |
8,431,903 |
9,527,051 |
||||||
|
Salaries and payroll-related costs |
3,986,367 |
4,276,105 |
||||||
|
General and administrative expenses |
1,671,185 |
1,854,174 |
||||||
|
Stock-based compensation |
2,092,541 |
2,424,442 |
||||||
|
Depreciation and amortization |
|
1,141,173 |
|
|
1,185,611 |
|
||
|
TOTAL OPERATING EXPENSES |
|
17,323,169 |
|
|
19,267,383 |
|
||
|
OPERATING LOSS |
(13,813,348 |
) |
(14,901,887 |
) |
||||
|
OTHER INCOME/(EXPENSE), PROVISION FOR INCOME TAXES |
|
614,470 |
|
|
2,815,779 |
|
||
|
NET LOSS |
$ |
(13,198,878 |
) |
$ |
(12,086,108 |
) |
||
|
|
||||||||
|
NET LOSS PER SHARE (BASIC AND DILUTED): |
$ |
(0.18 |
) |
$ |
(0.17 |
) |
||
|
WEIGHTED AVERAGE SHARES OUTSTANDING |
|
74,831,415 |
|
|
71,444,600 |
|
||
|
|
||||||||
|
FINANCIAL POSITION SUMMARY |
December 31, |
September 30, |
||||||
|
2017 |
2017 |
|||||||
|
CASH AND CASH EQUIVALENTS |
$ |
11,531,345 |
$ |
24,838,567 |
||||
|
SHORT-TERM INVESTMENTS |
|
39,169,376 |
|
|
40,769,539 |
|
||
|
TOTAL CASH RESOURCES (CASH AND INVESTMENTS) |
|
50,700,721 |
|
|
65,608,106 |
|
||
|
OTHER ASSETS |
|
37,519,772 |
|
|
38,414,174 |
|
||
|
TOTAL ASSETS |
|
88,220,493 |
|
|
104,022,280 |
|
||
|
TOTAL LIABILITIES |
18,021,183 |
23,155,118 |
||||||
|
TOTAL STOCKHOLDERS’ EQUITY |
|
70,199,310 |
|
|
80,867,162 |
|
||
|
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY |
$ |
88,220,493 |
|
$ |
104,022,280 |
|
||
|
|
||||||||
|
SHARES OUTSTANDING |
74,917,876 |
74,785,426 |
||||||
|
|
||||||||
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable
diseases by silencing the genes that cause them. Using a broad portfolio
of RNA chemistries and efficient modes of delivery, Arrowhead therapies
trigger the RNA interference mechanism to induce rapid, deep, and
durable knockdown of target genes. RNA interference, or RNAi, is a
mechanism present in living cells that inhibits the expression of a
specific gene, thereby affecting the production of a specific protein.
Arrowhead’s RNAi-based therapeutics leverage this natural pathway of
gene silencing.
For more information, please visit www.arrowheadpharma.com,
or follow us on Twitter @ArrowheadPharma.
To be added to the Company’s email list and receive news directly,
please visit http://ir.arrowheadpharma.com/alerts.cfm.
Safe Harbor Statement under the Private Securities Litigation Reform
Act:
This news release contains forward-looking statements within the
meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our actual
results may differ materially and adversely from those expressed in any
forward-looking statements as a result of various factors and
uncertainties, including the safety and efficacy of our product
candidates, the duration and impact of regulatory delays in our clinical
programs, our ability to finance our operations, the future success of
our scientific studies, our ability to successfully develop drug
candidates, the timing for starting and completing clinical trials,
rapid technological change in our markets, and the enforcement of our
intellectual property rights. Our most recent Annual Report on Form 10-K
and subsequent Quarterly Reports on Form 10-Q discuss some of the
important risk factors that may affect our business, results of
operations and financial condition. We assume no obligation to update or
revise forward-looking statements to reflect new events or circumstances.
Source: Arrowhead Pharmaceuticals, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180209005693/en/
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
or
Investors
and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
britchie@lifesciadvisors.com
www.lifesciadvisors.com
Source: Arrowhead Pharmaceuticals Inc.
News Provided by Acquire Media